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Abstract
Background: Recently, miR-451 as a tumor suppressor has been reported in other studies. However, whether miR-
451 can affect the sensitivity of non-small cell lung cancer (NSCLC) cells to cisplatin (DDP) remains unclear. The aim
of this study is to evaluate the roles of miR-451 in the sensitivity of NSCLC cells to DDP.
Methods: Quantitative RT-PCR assay was performed to detect the expression of miR-451 in 10 pairs of NSCLC and
noncancerous tissue samples. pcDNA-GW/EmGFP-miR-451 was stably transfected into NSCLC cell line (A549). Then,
the effects of miR-451 upregulation on growth, colony formation and apoptosis of A549 cells were investigated.
Finally, the effects of miR-451 upregulation on in vitro and in vivo sensitivity of A549 cells of DDP were also
determined.
Results: The level of miR-451 expression in NSCLC tissues was significantly higher than that in corresponding
noncancerous tissues. Ectopic overexpression of miR-451 could significantly inhibit growth and induce apoptosis of
A549 cells. Moreover, ectopic overexpression of miR-451 could sensitize A549 cells to DDP possibly by increasing
DDP-induced apoptosis which might be associated with the inactivation of Akt signaling pathway.
Conclusions: This study demonstrated for the first time that combination of DDP application with miR-451
upregulation might be a potential strategy for the treatment of human NSCLC.
Background
NSCLC accounts for the majority of lung cancer cases
and chemotherapy has been the mainstay of treatments
of lung cancers [1]. Up to date, DDP still remains the
most widely used first-line chemotherapeutic agent for
NSCLC treatment. However, continuous infusion or
multiple administration of DDP often cause severe side
effects, including myelosuppression, asthenia, and gas-
trointestinal disorders, as well as long-term cardiac,
renal, and neurological consequences [2]. Therefore,
improving the sensitivity to drug doses strategies is still
a challenge for chemotherapy efficacy. Novel therapeutic
modalities combining genetic and chemotherapeutic
approaches will play important roles in the fight against
cancer in future.
MicroRNAs (miRNAs) are small, endogenous non-
coding RNAs that have been identified as post-transcrip-
tional regulators of gene expression. MiRNAs exert their
functions through imperfect base-pairing with the 3’-
untranslated region (3’-UTR) of target mRNAs [3]. In
human cancer, miRNAs can act as oncogenes or tumour
suppressor genes during tumourigenesis. Evidence col-
lected to date shows the involvement of microRNA and
identifies this class of regulatory RNAs as diagnostic and
prognostic cancer biomarkers, as well as additional ther-
apeutic tools [4-6]. Meanwhile, the associations of dysre-
gulation of miRNAs with chemoresistance of human
cancers are attracting more and more attention [7].
Some researches have shown that dysregulation of miR-
NAs can contribute to the chemoresistance of cisplatin
in human tumor cells [8,9]. Recently miR-451 has been
reported to be induced during zebrafish, mouse, and
human erythroid maturation as an key factor involved
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in regulates erythrocyte differentiation [10-12]. It was
also reported that miR-451 might function as tumor
suppressor and modulate MDR1/P-glycoprotein
expression in human cancer cells [13]. Meanwhile,
miR-451 has been reported to be involved in resistance
of the MCF-7 breast cancer cells to chemotherapeutic
drug doxorubicin [14]. However, to our best knowl-
edge, there have been no reports about the association
of miR-451 expression with the sensitivity of NSCLC
cells to DDP.
In the present study, we identify miR-451 to be down-
regulated in human NSCLC and report for the first time
that upregulation of miR-451 can enhance DDP chemo-
sensitivity in NSCLC cell line (A549) by inducing apop-
tosis enhancement, which identifies miR-451 as a valid
therapeutic target in strategies employing novel multi-
modality therapy for patients with NSCLC.
Methods
Patients and tissue samples
A total of 10 pairs of matched NSCLC and noncancer-
ous tissue samples were surgically obtained from
patients in Nanjing Chest Hospital, Jisnsu Province and
diagnosed by an independent pathologist. None of the
patients had received chemotherapy or radiotherapy
before surgery. Samples were snap-frozen in liquid
nitrogen and stored at -80°C until RNA extraction.
Written informed consent was obtained from all
patients before surgery.
Cell culture
NSCLC cell line (A549) was cultured in Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum, 100 U/mL
penicillin, and 100 μg/mL streptomycin. All cell lines
were cultured under the atmosphere of 5% CO2 with
humidity at 37°C.
Plasmid construction
The precursor sequence of miR-451 generated by anneal-





TAATGGTAACGGTTTC-3’) was digested with BamHI
and BglII and cloned into the BamHI-BglII fragment of
the pcDNA-GW/EmGFP-miR vector (GenePharma,
Shanghai, China). A construct including the non-specific
miR-NC (99 bp) was used as a negative control. The
constructed vectors were named pcDNA-GW/EmGFP-
miR-451 and pcDNA-GW/EmGFP-miR-NC, respectively.
Cell transfection
A549 cells were seeded into 6-well plates and trans-
fected with the miR-415-expressing vector or the con-
trol vector expressing a non-specific miR-NC using
Lipofectamine 2000 (Invitrogen), and were selected with
spectinomycin (100 μg/ml) to generate two stable
monoclonal cell lines (a miR-218 stable cell line, A549/
miR-451, and a control stable cell line, A549/miR-NC).
Quantitative real-time polymerase chain reaction (qRT-
PCR) assay
Total RNA was extracted using TRIzol reagent (Invitro-
gen, CA, USA). Reverse-transcribed complementary
DNA was synthesized with the Prime-Script RT reagent
Kit (TaKaRa, Dalian, China). Realtime polymerase chain
reaction (PCR) was performed with SYBR Premix Ex
Taq (TaKaRa, Dalian, China). For miRNA detection,
mature miR-451 was reverse-transcribed with specific
RT primers (miR-451: 5’-CTCAACTGGTGTCGTG-
GAGTCGGCAATTCAGTTGAGAAA-CTCAG-3’ and U6:
5’-TGGTGTCGTGGAGTCG-3’) quantified with a Taq-
Man probe, and normalized by U6 small nuclear RNA
using TaqMan miRNA assays (Applied Biosystems, CA).
Stem-loop conventional RT-PCR assay
Total RNA was extracted using TRIzol reagent (Invitro-
gen, USA). Reverse-transcribed complementary DNA
was synthesized with the Prime-Script RT reagent Kit
(TaKaRa, Dalian, China). Conventional PCR was used to
assay miRNA expression with the specific forward pri-
mers and the universal reverse primer complementary
to the anchor primer. U6 was used as internal control
(Invitrogen, USA). The PCR primers for mature miR-
451 or U6 were designed as follows: miR-451 sense, 5’-
ACACTCCAGCTGGGAAACCGTTACCATTACT-3’ and
reverse, 5’-CTGGTGTCGTGGAGTCGGCAA-3’. U6
sense, 5’- CTCGCTTCGGCAGCACA-3’ and reverse, 5’-
AACGCTTCACGAATTTGCGT-3’. Then, the RT-PCR
products were electrophoresed through a 1.5% agarose
gel with ethidium bromide. Signals were quantified by
densitometric analysis using the Labworks Image Acqui-
sition (UVP, Inc., Upland, CA).
Western Blot assay
Thirty micrograms of protein extract were separated in
a 15% SDS-polyacrylamide gel and electrophoretically
transferred onto a PDVF membrane (Millipore, Nether-
lands). Membranes were blocked overnight with 5%
non-fat dried milk and incubated for 2 h with antibodies
to phospharylated Akt (pAkt-473), total Akt, Bcl-2 and
Bax (Santa Cruz Biotechnology, Santa Cruz, CA) and
GAPDH (Sigma, USA). After washing with TBST
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(10 mM Tris, pH 8.0, 150 mMNaCl, and 0.1% Tween
20), the membranes were incubated for 1 h with horse-
radish peroxidase-linked goat-anti-rabbit antibody. The
membranes were washed again with TBST, and the pro-
teins were visualized using ECL chemiluminescence and
exposed to x-ray film.
3-(4,5-dimethylthazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay
The mock or stably transfected A549 cells were seeded
into 96-well plates (6.0 × 103 cells/well) and allowed to
attach overnight. After cellular adhesion, freshly pre-
pared anticancer drugs (DDP) were added with various
concentrations. After 72 h, cell viability was assessed
using MTT assay. The absorbance at 490 nm (A490) of
each well was read on a spectrophotometer. Three inde-
pendent experiments were performed in quadruplicate.
Colony formation assay
Approximately 500 mock A549 or stable transfect A549
cells (A549/miR-451 and A549/miR-NC) were placed in a
fresh 6-well plate with or without DDP for another 12 h
and maintained in RMPI 1640 containing 10% FBS for
2 weeks. Colonies were fixed with methanol and stained
with 0.1% crystal violet in 20% methanol for 15 min.
Flow cytometry analysis of apoptosis
Cells were treated with or without DDP for another 12 h
and harvested and fixed with 2.5% glutaraldehyde for
30 minutes. After routine embedment and section, the
cells were observed under electronic microscope. The
apoptosis rates were determined using Annexin V-FITC
and PI staining flow cytometry.
Hoechst staining assay
Cells were cultured on 6-well tissue culture plates to
confluence and treated with or without DDP for another
12 h. Then, Hoechst 33342 (Sigma, USA) was added to
the culture medium of living cells; changes in nuclear
morphology were detected by fluorescence microscopy
using a filter for Hoechst 33342 (365 nm). The percen-
tages of Hoechst-positive nuclei per optical field (at
least 50 fields) were counted.
Caspase-3 activity
The activity of Caspase-3 was measured using Caspase-3
Colorimetric Assay Kit (Nanjing Keygen Biotech. Co.,
Ltd) following the manufacturer’s instruction. In brief,
cells were seeded in the 6-wells and were cultured for
24 h. Then, the cells were administered with or without
DDP for another 12 h and harvested, resuspended in
50 μL of lysis buffer and incubated on ice for 30 min,
and cellular debris was pelleted. The lysates (50 μL)
were transferred to 96-well plates. The lysates were
added to 50 μL 2.0 × Reaction Buffer along with 5 μL
Caspase-3 Substrate and incubated for 4 h at 37°C, 5%
CO2 incubator. The activities were quantified spectro-
photometrically at a wavelength of 405 nm.
Terminal Transferase dUTP Nick End Labeling (TUNEL)
Assay
Tissues were plated on polylysine-coated slides, fixed with
4% paraformaldehyde in 0.1 M phosphate-buffered saline
(PBS) for 1 h at 25°C, rinsed with 0.1 M PBS, pH 7.4, and
permeabilized with 1% Triton X-100 in 0.01 M citrate buf-
fer (pH 6.0). DNA fragmentation was detected using
TUNEL Apoptosis Detection Kit (Nanjing KeyGen, China),
which specifically labeled 3’-hydroxyl termini of DNA
strand breaks using fluorescein isothiocyanate (FITC)-con-
jugated dUTP. DNA was also labeled with FITC DNA-
binding dye for 5 min. FITC labels were observed with a
fluorescence microscope. The percentage of apoptotic cells
was calculated as the number of apoptotic cells per number
of total cells × 100%.
Animal experiment
All experimental procedures involving animals were in
accordance with the Guide for the Care and Use of
Laboratory Animals and were performed according to
the institutional ethical guidelines for animal experi-
ment. Each aliquot of mock or stably transfected A549
cells were injected into the flanks of BALB/c nude mice
(Nu/Nu, female, 4-6 weeks old) which were purchased
from the Experimental Animal Centre of Nanjing Medi-
cal University and maintained under pathogen-free con-
ditions (n = 8/group). One day after tumor cell
implantation, mice were treated with CDDP (3.0 mg/kg
body weight; i.p., thrice/week), Tumor volume was fol-
lowed up for 4 weeks and measured once weekly. The
tumor volume formed was calculated by the following
formula: V = 0.4 × D × d2 (V, volume; D, longitudinal
diameter; d, latitudinal diameter). All mice were killed
and s.c. tumors were resected and fixed in 10% PBS.
TUNEL staining assay was performed on 5 μm sections
of the excised tumors. The number of apoptotic cells in
five random high-power fields was counted.
Statistical analysis
All experimental data were shown as the mean ± SEM.
Differences between samples were analyzed using the
Student’s t test. Statistical significance was accepted at
P < 0.05.
Results
MiR-451 is significantly downregulated in human NSCLC
tissues
In this study, a stem-loop qRT-PCR assay was performed
to determine the expression of miR-451 in 10 pairs of
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matched NSCLC and noncancerous lung tissue sam-
ples. As shown in Figure 1A, the expression levels of
miR-451in NSCLC tissues were less than approximately
36.4% of those in noncancerous lung tissues. In addi-
tion, conventional RT-PCR assay was also performed
to analyze the expression of miR-451 in 2 pairs of
matched NSCLC and noncancerous tissue samples.
The gel electrophoresis of RT-PCR products confirmed
the downregulation of miR-451 expression in NSCLC
tissues (Figure 1B). Therefore, it was concluded that
the downregulation of miR-451 might be involved in
lung carcinogenesis.
The expression of miR-451 could be significantlu
upregulated in A549 cells by pcDNA-GW/miR-45
To upregulate the expression of miR-451 in NSCLC cell
line (A549), pcDNA-GW/miR-451 was transfected and
stable transfectants (A549/miR-451 or A549/miR-NC)
were successfully established. As shown in Figure 2A,
qRT-PCR assay showed that the relative level of miR-
451 expression in A549/miR-451 could be significantly
upregulated by 3.8-fold compared with that in mock
A549 or A549/miR-NC cells (P < 0.05). The gel electro-
phoresis of RT-PCR products confirmed the upregula-
tion of miR-451 expression in A549/miR-451 cells
(Figure 2B).
Upregulation of miR-451 inhibits growth and enhances
apoptosis of NSCLC cell line (A549)
To analyze the effect of miR-451 expression on pheno-
types of NSCLC cell line, we performed MTT, colony
formation and flow cytometric assays. As shown in Fig-
ure 3A, A549/miR-451 cell line had a significant
increase in cell viability compared with mock A549 or
A549/miR-NC cell line (P < 0.05). The number of colo-
nies formed from A549/miR-451 cells was significantly
lower than that formed from mock A549 or A549/miR-
NC cells (P < 0.05; Figure 3B). Moreover, flow cyto-
metric analysis showed that the apoptotic rate of A549/
miR-451 cells (11.6 ± 1.5%) was significantly higher than
that of mock A549 or A549/miR-NC cells (P < 0.05;
Figure 3C). Thus, upregulation of miR-451 could induce
growth inhibition and apoptosis enhancement in A549
cells.
Upregulation of miR-451 expression inactivates the Akt
signaling pathway of A549 cells
It has been reported that activation of the Akt signaling
pathway can regulate many biological phenomena of
lung cancer cells, such as cell proliferation and survival,
motility and migration. Thus, we analyzed the effects of
miR-451 on the Akt signaling pathway in A549 cells
(Figure 4A). Results showed that the upregulation of
Figure 1 Detection of miR-451 expression in tissue samples. A. Quantitative RT-PCR analysis of miR-451 expression in 10 cases of NSCLC and
corresponding noncancerous tissues. **P < 0.01. N: noncancerous tissues; T: tumor tissues. B. Conventional stem-loop RT-PCR analysis of miR-451
expression in NSCLC and corresponding noncancerous tissues. Gel images of electrophoresis. U6 was used as an internal control. All experiments
were performed in triplicate.
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miR-451 could significantly downregulate the expression
of pAkt protein but had no effects on the expression of
total Akt protein. Additionally, the expression of Bcl-2
protein was downregulated and the expression of Bax
protein was upregulated. The activity of caspase-3 in
A549/miR-451 cells was also found to be significantly
enhanced compared with that in mock A549 or A549/
miR-NC cells (P < 0.05; Figure 4B). Therefore, it was
concluded that the elevation of caspase-3 activity might
be induced by the elevated ratio of Bax/Bcl-2. However,
the exact mechanisms of miR-451 affecting the Akt sig-
naling pathway need to be elucidated in future.
Upregulation of miR-451 enhances in vitro sensitivity of
A549 cells to DDP
Dysregulation of miRNA expression has been reported
to be associated with chemoresistance of human can-
cers. However, whether miR-451 expression affects the
sensitivity of NSCLC cells is not fully understood. To
determine this, the mock or stably transfected A549
cells were treated with various concentrations (0, 5, 10,
15, 20 and 25 μg/ml) of DDP for 12 h or 5 μg/ml of
DDP for 0, 12, 24, 26 and 48 h. The results from MTT
assay indicated that upregulation of miR-451 led to a
significant decrease in cell viability of A549 cells in
response to DDP in a dose- or time -dependent manner
compared with those of A549/miR-NC and mock A549
cells (Figure 5A and 5B). The cells were treated 5 μg/ml
DDP for 12 h and the number of colonies was deter-
mined. As shown in Figure 5C, the number of colonies
formed from A549/miR-451 cells treated with DDP was
significantly lower than that formed from A549/miR-NC
and mock A549 cells (P < 0.05). These data obviously
showed that upresgulation of miR-451 might effectively
enhance the sensitivity of A549 cells to DDP.
Upregulation of miR-451 enhances DDP-induced
apoptosis of A549 cells
The precise underlying mechanisms by which upregula-
tion of miR-451 enhances chemosensitivity of A549 cells
to DDP were further investigated. Then, the apoptosis
was detected by flow cytometric assay. As shown in Fig-
ure 6A, the apoptotic rare of A549/miR-451 treated
with 5 μg/ml DDP was increased by approximately
11.7% in comparison with mock A549 cells treated with
5 μg/ml DDP (P < 0.05). However, the apoptotic rate of
A549/miR-NC cells treated with DDP showed no signifi-
cant difference compared with that of mock A549 cells
treated with DDP (P > 0.05). Figure 6B showed the
results of AnnexinV-FITC apoptosis detection assay,
which confirmed the results of flow cytomeric assay.
Finally, the activity of caspase-3 was also determined by
Figure 2 Detection of miR-451 expression in mock or stably transfected A549 cells. A. Quantitative RT-PCR analysis of miR-451 expression
in A549, A549/miR-NC or A549/miR-451 cells. B. Conventional stem-loop RT-PCR analysis of miR-451 expression in A549, A549/miR-NC or A549/
miR-451 cells. Gel images of electrophoresis. U6 was used as an internal control. All experiments were performed in triplicate.
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Figure 3 Effect of miR-451 upregulation on growth and apoptosis of A549 cells. A. MTT analysis of cell viability in mock A549, A549/miR-
NC or A549/miR-451 cells. *P < 0.05. B. Detecting colony formation ability of mock A549, A549/miR-NC or A549/miR-451 cells, *P < 0.05. C. Flow
cytomerty analysis of apoptosis in mock A549, A549/miR-NC or A549/miR-451, *P < 0.05; N.S, P > 0.05. All experiments were performed in
triplicate.
Figure 4 Effect of miR-451 upregulation on the Akt signaling pathway. A. Western Blot analysis of pAkt (473), total Akt, Bcl-2 and Bax
protein expression in mock A549, A549/miR-NC or A549/miR-451 cells. GAPDH was used as an internal control. B. Analysis of relative caspase-3
activity in mock A549, A549/miR-NC or A549/miR-451 cells. All experiments were performed in triplicate.
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colorimetric assay. As shown in Figure 6C, the caspase-3
activity in A549/miR-451 cells treated with DDP
remarkably increased by approximately 308% compared
that mock A549 or A549/miR-NC cells treated with
DDP (P < 0.05). Therefore, upregulation of miR-451
might increase DDP chemosensitivity of A549 cells by
enhancing DDP-induced apoptosis.
Upregulation of miR-451 increases in vivo
chemosensitivity of A549 cells to DDP
To explore whether upregulation of miR-451 on chemo-
sensitivity of A549 cells to DDP in vivo, s.c. tumors
were developed in nude mice followed by treatment
with DDP or PBS. As shown in Figure 7A, the tumors
formed from A549/miR-451cells grew significantly
slower than those from A549/miR-NC after the treat-
ment with DDP. At 28 days after inoculation, the aver-
age tumor volume of A549/miR-451 cells (212 ± 36
mm3) was significantly lower than that of A549/miR-NC
(323 ± 13 mm3) following DDP treatment (P < 0.05;
Figure 7B). TUNEL assay showed that the apoptotic rate
of tumors developed from A549/miR-451 cells (15.8 ±
2.2%) was significantly higher than that of tumors devel-
oped from A549/miR-NC cells (9.6 ± 1.5%) following
DDP treatment (P < 0.05; Figure 7C). Like the results
observed from in vitro experiments, upregulation of
miR-451 could also increase in vivo chemosensitivity of
A549 cells to DDP by inducing apoptosis enhancement.
Discussion
MiRNAs are a growing class of small, noncoding RNAs
(17-27 nucleotides) that regulate gene expression by tar-
geting mRNAs for translational repression, degradation,
or both. Increasing evidence suggests that deregulation
of miRNAs has been frequently observed in tumor tis-
sues. These miRNAs have regulatory roles in the patho-
genesis of cancer in humans, through the suppression of
genes involved in cell proliferation, differentiation, apop-
tosis, metastasis and resistance [15-18]. Recently, many
studies have shown that miRNAs play an important role
Figure 5 Effect of miR-451 upregulation on the in vitro sensitivity of A549 cells to DDP. A. Effects of various concentrations (0, 5, 10, 15,
20 and 25 μg/ml) of DDP on cells (mock A549, A549/miR-NC or A549/miR-451) for 12 h assessed by MTT assay. B. Effects of 5 μg/ml DDP on
cells (mock A549, A549/miR-NC or A549/miR-451) for varied time length (0, 12, 24, 36 and 48 h) evaluated by MTT assays. C. Effects of 5 μg/ml
DDP on colony formation of cells (mock A549, A549/miR-NC or A549/miR-451). All experiments were performed in triplicate, *P < 0.05.
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Figure 6 Effect of combined miR-451 upregulation with DDP (5 μg/ml) on apoptosis of A549 cells. A. Flow cytometry analysis of
apoptosis in mock A549, A549/miR-NC or A549/miR-451 cells. B. Hoechst staining analysis of apoptosis in mock A549, A549/miR-NC or A549/
miR-451 cells. C. Analysis of relative caspase-3 activity in mock A549, A549/miR-NC or A549/miR-451 cells. All experiments were performed in
triplicate.
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in malignant transformation. It is likely, therefore, that
they can also modulate sensitivity and resistance to
anticancer drugs in substantial ways. The mechanisms
responsible for chemotherapy resistance by miRNAs
have not been clearly identified. Current published data
on the association of miRNAs with chemoresistance are
limited. While altered expression of miRNAs in primary
human NSCLCs has been used for tumor diagnosis and
prognosis [19], the potential involvement of miRNAs in
induction of drug resistance, particularly, in cisplatin
resistance has not been explored.
Here, we showed that miR-451 is frequently downre-
gulated in human NSCLC tissues compared with corre-
sponding noncancerous lung tissues, which is consistent
with the results of Gao’et al [20]. It was also reported
that microRNA-451 could regulate macrophage migra-
tion inhibitory factor production and proliferation of
gastrointestinal cancer cells [21]. Nan and his colleagues
Figure 7 Effect of miR-451 upregulation on the in vivo sensitivity of A549 cells to DDP. A. Growth of tumors in the mice injected with
A549/miR-451 or A549/miR-451 with or without DDP treatement. The inoculation was performed in eight mice. B. Average tumor volume at day
28 after the inoculation of A549/miR-NC or A549/miR-451 cells with or without DDP treatment (n = 8/group). C. TUNEL staining analysis of
apoptosis in tumor tissues at day 28 after the inoculation of A549/miR-NC or A549/miR-451 cells with or without DDP treatment (n = 8/group).
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revealed that miR-451 impacts glioblastoma cell prolif-
eration, invasion and apoptosis, perhaps via regulation
of the PI3K/AKT signaling pathway [22]. Thus, miR-451
was proposed as a tumor-suppressor of human cancers.
In other reports, Godlewski and his colleagues showed
that miRNA-451 regulates LKB1/AMPK signaling and
allows adaptation to metabolic stress in glioma cells,
which represents a fundamental mechanism that contri-
butes to cellular adaptation in response to altered
energy availability [23]. At the same time, they also
identified a potential feedback loop between LKB1 and
miR-451, which allows a sustained and robust response
to glucose deprivation [24]. P-glycoprotein, which is the
MDR1 gene product, confers cancer cell resistance to
a broad range of chemotherapeutics. Zhu, et al demon-
strate for the first time the roles of miRNAs in the
regulation of drug resistance mediated by MDR1/
P-glycoprotein, and suggest the potential for targeting
miR-27a and miR-451 as a therapeutic strategy for
modulating MDR in cancer cells [13]. Olga and his
colleagues reported that the enforced increase of miR-
451 levels in the MCF-7/DOX cells down-regulates
expression of mdr1 and increases sensitivity of the
MCF-7-resistant cancer cells to DOX [14]. All these
data provide a strong rationale for the development of
miRNA-based therapeutic strategies aiming to overcome
chemoresistance of tumor cells. However, whether the
expression of miR-451 can affect the sensitivity of lung
cancer cells to DDP is still unclear.
In the present study, we found that the upregulation
of miR-451 could significantly inhibit growth and colony
formation of NSCLC cell line (A549). Upregulation of
miR-451 could also enhance caspase-3-dependent apop-
tosis of A549 cells by inactivating the Akt signalling
pathway which induced the reverse of Bcl-2/Bax ratio.
Furthermore, upregulation of miR-451 could signifi-
cantly increase the in vitro and in vivo sensitivity of
A549 cells to DDP. To the best of our knowledge, we
provided the first insight into the roles and possible
mechanisms of miR-451 upregulation in chemosensitiv-
ity of A549 cells to DDP. These data suggest that appro-
priate combination of DDP application with miR-451
regulation might be a potential approach to NSCLC
therapy. For higher-dose DDP would produce potentially
serious toxic effects such as nephro- and ototoxicity
would be increased, combination of DDP application
with miR-451 upregulation for the treatment of NSCLC
would contribute to lower-dose DDP administration and
result in a reduction of DDP toxic side-effects. Although
inhibition of Akt signal pathway has been reported to be
able to improve chemotherapeutic effect of human
tumor cells, whether upregulation of miR-451 enhance
DDP chemosensitivity of A549 cells by inactivating the
Akt signal pathway needs to be further elucidated.
Moreover, only A549 cell line has been used in this
study, further researches should be conducted on other
cell lines to testify our experimental data.
In conclusion, upregulation of miR-451 could increase
the sensitivity of A549 cells to DDP both in vitro and in
vivo, suggesting that appropriate combination of DDP
application with miR-451 upregulation might be a
potential strategy for the treatment of human NSCLC in
future.
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